Imperial inventors have created novel gene circuits suitable for manipulating Mycoplasma growth in vivo. In the absence of natural inducible systems, three well-known repressor systems have been engineered to be genetic switches in M. pneumoniae. Accordingly, expression of these three transcriptional factors has been optimised for M. pneumoniae and new synthetic inducible promoters have been designed for each case.
Imperial inventors have additionally developed a set of synthetic gene switches that can be used to provide genetic barriers preventing growth and proliferation of Mycoplasma in vivo. Switches are designed so that they may limit Mycoplasma growth to bioreactors in the presence of added compounds. This can, for example, enable selective in vivo attenuation of a M. pneumoniae chassis used for live vaccines, thus maximising vaccine immunogenicity while increasing biosafety.
- Novel genetic engineering tools that can be applied to Mycoplasma expanding its utility as a synthetic biology asset.
- Combined auxotrophic, killswitch synthetic circuits to allow Mycoplasma chassis to be grown in bioreactors in the presence of added compounds, while preventing growth and proliferation in vivo.
- This enables selective in vivo attenuation of M. pneumoniae for live vaccines, thus maximising immunogenicity while increasing biosafety.
This technology is subject to Priority patent application.
+44 (0)20 7594 6866